NCT07293247ClinicalTrials.gov
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer With Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)
בקצרה
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining…
שלב 2דרושים 164 משתתפים125 אתריםמדינה אחת
קטגוריות
רשום במרשם אחד
- ClinicalTrials.govNCT07293247פתיחת רשומה זו ב־ClinicalTrials.govסונכרן לפני שבועיים
מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.
מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.
מתעניינים במחקר הזה?
התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-12-19; recorded start 2026-10-14
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 97 other studies in this databaseCounted from the lead sponsor named in the record (Alliance for Clinical Trials in Oncology)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: other.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding0/20
Open-label
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 33 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A small study: 164 participants (target), run at 125 sites.
How this score is built
- Enrolment21/40
164 participants (target)
- Site count18/25
33 sites
- Country count0/15
Single country
- Planned duration10/10
Planned over about 69 months
- Sponsor scale7/10
Alliance for Clinical Trials in Oncology has led 96 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
תקציר
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining lymph node cancer after surgery. Radiation therapy uses high-energy X-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding I²-PORT radiation therapy to standard therapy may be more effective than standard therapy alone in reducing the risk of cancer returning in those who have undergone surgery for NSCLC.
מצבים רפואיים
- Lung Non-Small Cell Carcinoma
זכאות
| מין | הכול |
|---|---|
| גילאים | 18 Years – ללא מקסימום |
| מתנדבים בריאים | לא |
זכאות כפי שנכתבה במרשם
זכאות במשפטים פשוטים
הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.
תכנון המחקר
| סוג המחקר | התערבותי |
|---|---|
| שלב | שלב 2 |
| הקצאה | אקראי |
| מודל ההתערבות | PARALLEL |
| מטרה ראשית | TREATMENT |
| הסתרה | NONE (0) |
| גיוס | דרושים 164 משתתפים |
נותן חסות ושותפים
- Alliance for Clinical Trials in Oncology נותן חסות
- National Cancer Institute (NCI) שותפים
זרועות והתערבויות
- Arm I (SOC chemotherapy/immunotherapy)ACTIVE_COMPARATOR
Patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.
- Arm II (I²-PORT, SOC chemotherapy/immunotherapy)EXPERIMENTAL
Patients undergo I²-PORT QD Monday through Friday over 15-25 fractions over 5-6 weeks. Starting 1-42 days after completion of I²-PORT, patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.
התערבויות
- פרוצדורה Biospecimen Collection
Undergo blood sample collection
- תרופה Chemotherapy
Receive standard of care chemotherapy
- פרוצדורה Computed Tomography
Undergo CT
- אחר Fludeoxyglucose F-18
Undergo FDG PET scan
- אחר Immunotherapy
Receive standard of care immunotherapy
- קרינה Intensity-Modulated Radiation Therapy
Undergo I²-PORT
- פרוצדורה Magnetic Resonance Imaging
Undergo MRI
מדדי תוצאה
מדד תוצאה ראשוני
Disease-free survival (DFS)
DFS will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. The median DFS for each treatment group will be estimated, and its 80% and 90% confidence intervals will be calculated using the Kaplan-Meier estimator. Additionally, the 24-month DFS rate for each treatment arm, along with its confidence intervals, will be calculated.
מסגרת זמן Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years
מדד תוצאה ראשוני
Incidence of late grade ≥ 3 cardiopulmonary toxicities
Will be assessed according to the Common Terminology Criteria for Adverse Events version 5.0. Will be estimated for each treatment group and the difference between the two treatment groups. The confidence intervals of the rate difference at 80% and 90% significance levels will be estimated using the Miettinen-Nurminen method.
מסגרת זמן Between 3 and 24 months after protocol therapy
מדד תוצאה משני
5-year DFS
DFS will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1
מסגרת זמן Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years
מדד תוצאה משני
2-year overall survival (OS)
Will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. Multivariable Cox models will evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, pre-treatment, histology, and performance status.
מסגרת זמן Time from the date of randomization to death from all causes, assessed up to 2 years
מדד תוצאה משני
5-year OS
Will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. Multivariable Cox models will evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, pre-treatment, histology, and performance status.
מסגרת זמן Time from the date of randomization to death from all causes, assessed up to 5 years Symptomatic skeletal event free survival (SSE-FS)
מדד תוצאה משני
Patient-reported symptoms
Will be assessed using Patient Reported Outcomes - Common Terminology Criteria for Adverse Events and will be evaluated for between-arm differences in proportions of patients with a maximum post-baseline score greater than 0 using Fisher's exact or chi-square test.
מסגרת זמן up to 5 years
תאריכים
| תאריך התחלה | 14 באוקטובר 2026 (משוער) |
|---|---|
| סיום ראשוני | 31 בדצמבר 2032 (משוער) |
| סיום | 1 במרץ 2036 (משוער) |
| פורסם לראשונה | 19 בדצמבר 2025 (בפועל) |
| עודכן לאחרונה | 3 בנובמבר 2026 |
| התוצאות פורסמו | לא צוין ברשומת המרשם |
| המצב אומת לאחרונה | נובמבר 2026 |
בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.
מיקומים
121 אתרים מגייסים
United States
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor | Michigan | מגייס |
| Northwest Wisconsin Cancer Center | Ashland | Wisconsin | מגייס |
| Duluth Clinic Ashland | Ashland | Wisconsin | מגייס |
| Mount Sinai Comprehensive Cancer Center at Aventura | Aventura | Florida | מגייס |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | מגייס |
| MaineHealth Coastal Cancer Treatment Center | Bath | Maine | מגייס |
| UPMC-Heritage Valley Health System Beaver | Beaver | Pennsylvania | מגייס |
| Sanford Joe Lueken Cancer Center | Bemidji | Minnesota | מגייס |
| Sanford Bismarck Medical Center | Bismarck | North Dakota | מגייס |
| Illinois CancerCare-Bloomington | Bloomington | Illinois | מגייס |
| OSF Saint Joseph Medical Center | Bloomington | Illinois | מגייס |
| Essentia Health Saint Joseph's Medical Center | Brainerd | Minnesota | מגייס |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Michigan | מגייס |
| Trinity Health Medical Center - Brighton | Brighton | Michigan | מגייס |
| MaineHealth Cancer Care and IV Therapy - Brunswick | Brunswick | Maine | מגייס |
| Trinity Health Medical Center - Canton | Canton | Michigan | מגייס |
| Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Michigan | מגייס |
| Illinois CancerCare-Canton | Canton | Illinois | מגייס |
| Saint Francis Medical Center | Cape Girardeau | Missouri | מגייס |
| Carlisle Regional Cancer Center | Carlisle | Pennsylvania | מגייס |
| Illinois CancerCare-Carthage | Carthage | Illinois | מגייס |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | מגייס |
| Medical University of South Carolina | Charleston | South Carolina | מגייס |
| Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Michigan | מגייס |
| Chelsea Hospital | Chelsea | Michigan | מגייס |
| Rush MD Anderson Cancer Center | Chicago | Illinois | מגייס |
| Clackamas Radiation Oncology Center | Clackamas | Oregon | מגייס |
| Baptist Memorial Hospital and Cancer Center-Collierville | Collierville | Tennessee | מגייס |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | מגייס |
| Memorial Sloan Kettering Commack | Commack | New York | מגייס |
| Cancer Care Specialists of Illinois - Decatur | Decatur | Illinois | מגייס |
| Decatur Memorial Hospital | Decatur | Illinois | מגייס |
| Essentia Health - Deer River Clinic | Deer River | Minnesota | מגייס |
| Essentia Health Cancer Center | Duluth | Minnesota | מגייס |
| Miller-Dwan Hospital | Duluth | Minnesota | מגייס |
| Essentia Health Saint Mary's Medical Center | Duluth | Minnesota | מגייס |
| Duke University Medical Center | Durham | North Carolina | מגייס |
| Marshfield Medical Center-EC Cancer Center | Eau Claire | Wisconsin | מגייס |
| UPMC Hillman Cancer Center Erie | Erie | Pennsylvania | מגייס |
| Illinois CancerCare-Eureka | Eureka | Illinois | מגייס |
| Sanford Roger Maris Cancer Center | Fargo | North Dakota | מגייס |
| Sanford Broadway Medical Center | Fargo | North Dakota | מגייס |
| Parkland Health Center - Farmington | Farmington | Missouri | מושהה |
| UPMC Cancer Center at UPMC Horizon | Farrell | Pennsylvania | מגייס |
| Illinois CancerCare-Galesburg | Galesburg | Illinois | מגייס |
| UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg | Pennsylvania | מגייס |
| UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg | Pennsylvania | מגייס |
| Memorial Sloan Kettering Westchester | Harrison | New York | מגייס |
| Essentia Health-Hayward Clinic | Hayward | Wisconsin | מגייס |
| Essentia Health Hibbing Clinic | Hibbing | Minnesota | מגייס |
75 אתרים נוספים מצוינים ברשומת המרשם.
מסמכי המחקר
לא צורפו מסמכים ברשומת מרשם זו.
שינויים לאורך זמן
- 3 בנובמבר 2026
אתר נוסף
14 sites added (125 total)
111125
- 19 באוקטובר 2026
תאריך הסיום נדחה
Primary completion delayed 1461 days
2028-12-312032-12-31
- 2 באוקטובר 2026
אתר נוסף
14 sites added (111 total)
97111
- 2 בספטמבר 2026
אתר נוסף
23 sites added (97 total)
7497
- 5 באוגוסט 2026
אתר נוסף
41 sites added (74 total)
3374